- Home
- ALLO vs VEL Comparison
ALLO vs VEL Comparison
Compare ALLO & VEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- VEL
- Stock Information
- Founded
- ALLO 2017
- VEL 2004
- Country
- ALLO United States
- VEL United States
- Employees
- ALLO N/A
- VEL N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- VEL Finance: Consumer Services
- Sector
- ALLO Health Care
- VEL Finance
- Exchange
- ALLO Nasdaq
- VEL Nasdaq
- Market Cap
- ALLO 438.2M
- VEL 660.6M
- IPO Year
- ALLO 2018
- VEL 2020
- Fundamental
- Price
- ALLO $1.92
- VEL $18.90
- Analyst Decision
- ALLO Strong Buy
- VEL Buy
- Analyst Count
- ALLO 10
- VEL 5
- Target Price
- ALLO $10.06
- VEL $20.80
- AVG Volume (30 Days)
- ALLO 3.0M
- VEL 81.3K
- Earning Date
- ALLO 11-07-2024
- VEL 03-06-2025
- Dividend Yield
- ALLO N/A
- VEL N/A
- EPS Growth
- ALLO N/A
- VEL 45.05
- EPS
- ALLO N/A
- VEL 1.84
- Revenue
- ALLO $43,000.00
- VEL $161,829,000.00
- Revenue This Year
- ALLO N/A
- VEL N/A
- Revenue Next Year
- ALLO N/A
- VEL $10.90
- P/E Ratio
- ALLO N/A
- VEL $10.24
- Revenue Growth
- ALLO 26.47
- VEL 35.27
- 52 Week Low
- ALLO $1.78
- VEL $14.51
- 52 Week High
- ALLO $5.78
- VEL $20.85
- Technical
- Relative Strength Index (RSI)
- ALLO 39.98
- VEL 36.08
- Support Level
- ALLO $2.11
- VEL $18.57
- Resistance Level
- ALLO $2.40
- VEL $19.07
- Average True Range (ATR)
- ALLO 0.17
- VEL 0.48
- MACD
- ALLO 0.00
- VEL -0.09
- Stochastic Oscillator
- ALLO 15.79
- VEL 19.70
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.